Panbela Therapeutics, Inc. (PBLA) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Panbela Therapeutics, Inc. (PBLA) trades at $0.0001 with AI Score 42/100 (Grade C). Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer treatment. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for PBLA: PBLA does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PBLA against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PBLA: the 3 scored disciplines are evenly split. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Panbela Therapeutics, Inc. (PBLA) Healthcare & Pipeline Overview
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for cancer, particularly pancreatic cancer. Their lead product, SBP-101, is in Phase Ia/Ib clinical trials. Trading on the OTC market, the company faces unique risks and liquidity challenges compared to exchange-listed peers.
What Is the Investment Thesis for PBLA?
Panbela Therapeutics presents a high-risk, high-reward investment opportunity characteristic of early-stage biotech companies. The primary value driver is the successful development and commercialization of SBP-101, targeting pancreatic cancer. Positive Phase Ia/Ib clinical trial results for SBP-101 would serve as a significant catalyst, potentially leading to increased investor interest and strategic partnerships. Conversely, clinical trial failures or regulatory setbacks could severely impact the company's valuation. The company's OTC listing introduces additional liquidity and transparency concerns. Investors should carefully weigh the potential upside against the inherent risks associated with clinical-stage biopharmaceutical companies before investing.
Based on FMP financials and quantitative analysis
PBLA Key Highlights
Panbela Therapeutics is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics, particularly for pancreatic cancer.
- The company's lead product candidate, SBP-101, is currently in Phase Ia/Ib clinical trials for metastatic pancreatic ductal adenocarcinoma.
- Panbela Therapeutics operates with a small team of 7 employees, reflecting a lean operational structure.
- The company trades on the OTC market, indicating higher risk and lower liquidity compared to exchange-listed companies.
- Panbela Therapeutics changed its name from Sun BioPharma, Inc. in December 2020 to reflect its evolving focus.
Who Are PBLA's Competitors?
PBLA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PBLA's Key Strengths?
Focus on a high unmet need in pancreatic cancer.
- Lead product candidate, SBP-101, in clinical trials.
- Experienced management team with expertise in drug development.
- Proprietary technology platform for developing novel cancer therapeutics.
What Are PBLA's Weaknesses?
Limited financial resources and reliance on external funding.
- High risk of clinical trial failure.
- Small team size and limited infrastructure.
- OTC market listing indicating higher risk and lower liquidity.
What Could Drive PBLA Stock Higher?
Release of Phase Ia/Ib clinical trial data for SBP-101 in metastatic pancreatic ductal adenocarcinoma.
- Exploration of strategic partnerships with larger pharmaceutical companies.
- Pursuit of orphan drug designation for SBP-101 in pancreatic cancer.
- Expansion of SBP-101 into other cancer indications.
What Are the Key Risks for PBLA?
Failure of SBP-101 in clinical trials.
- Regulatory delays or rejection of SBP-101.
- Competition from other companies developing cancer therapeutics.
- Limited financial resources and reliance on external funding.
- OTC market listing indicating higher risk and lower liquidity.
What Are the Growth Opportunities for PBLA?
- Advancement of SBP-101: The successful completion of Phase Ia/Ib clinical trials for SBP-101 and subsequent progression through later-stage trials represents a significant growth opportunity. Positive clinical data could attract partnerships with larger pharmaceutical companies, providing funding and resources for further development and commercialization.
- Expansion into Other Cancer Indications: Panbela is exploring the potential of SBP-101 and other agents in other cancer indications, such as neoadjuvant pancreatic cancer, colorectal cancer, and ovarian cancer. Successful expansion into these additional indications would broaden the company's market reach and revenue streams. Each of these cancer markets represents a multi-billion dollar opportunity, offering significant growth potential.
- Strategic Partnerships and Licensing Agreements: Forming strategic partnerships with larger pharmaceutical companies or licensing agreements for SBP-101 or other pipeline assets could provide Panbela with significant upfront payments, milestone payments, and royalties on future sales. These partnerships would also provide access to resources and expertise that could accelerate the development and commercialization of Panbela's products. This is an ongoing opportunity.
- Orphan Drug Designation: Seeking and obtaining orphan drug designation for SBP-101 in pancreatic cancer or other rare cancer indications could provide Panbela with market exclusivity, tax credits, and other incentives. Orphan drug designation can significantly enhance the commercial attractiveness of a drug and increase its likelihood of regulatory approval. This is an ongoing opportunity.
- Development of Novel Drug Delivery Systems: Investing in the development of novel drug delivery systems for SBP-101 or other pipeline assets could improve their efficacy and reduce side effects. This could lead to improved patient outcomes and increased market share. Novel drug delivery systems are a key area of innovation in the pharmaceutical industry, and Panbela could benefit from advancements in this field.
What Threats Does PBLA Face?
- Competition from larger pharmaceutical companies with more resources.
- Regulatory hurdles and delays in drug approval.
- Patent challenges and intellectual property disputes.
- Negative publicity or safety concerns related to SBP-101.
What Are PBLA's Competitive Advantages?
- Patent protection for SBP-101 and other pipeline assets.
- Proprietary knowledge and expertise in cancer drug development.
- Clinical data demonstrating the efficacy and safety of SBP-101.
- Potential for orphan drug designation for SBP-101 in pancreatic cancer.
What Does PBLA Do?
Panbela Therapeutics, Inc., established in 2011 and based in Waconia, Minnesota, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cancer treatment. Originally incorporated as Sun BioPharma, Inc., the company rebranded to Panbela Therapeutics, Inc. in December 2020 to reflect its evolving focus. The company's primary focus is on diseases affecting the pancreas, including pancreatitis and pancreatic cancer. Their research extends to other cancer indications, such as neoadjuvant pancreatic cancer, colorectal cancer, and ovarian cancer. Panbela's lead product candidate, SBP-101, is currently in Phase Ia/Ib clinical trials for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. Panbela operates with a small team of 7 employees, emphasizing a lean and focused approach to drug development. The company aims to address unmet medical needs in cancer therapy through the development of novel and disruptive therapeutics.
What Products and Services Does PBLA Offer?
- Develops disruptive therapeutics for cancer treatment.
- Focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer.
- Conducts clinical trials for its lead product candidate, SBP-101.
- Targets metastatic pancreatic ductal adenocarcinoma with SBP-101.
- Explores the potential of SBP-101 in other cancer indications, such as colorectal and ovarian cancer.
- Operates as a clinical-stage biopharmaceutical company.
How Does PBLA Make Money?
- Develops and patents novel cancer therapeutics.
- Conducts preclinical and clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA and other regulatory agencies.
- Potentially partners with larger pharmaceutical companies for commercialization or out-licensing.
What Industry Does PBLA Operate In?
Panbela Therapeutics operates within the competitive biotechnology industry, focusing on oncology. The oncology market is experiencing substantial growth, driven by an aging population and advancements in cancer diagnostics and treatments. Pancreatic cancer, in particular, represents a significant unmet medical need, making it a key target for biopharmaceutical companies. Competitors include companies like Advantagene, Inc. (ADVT), BioBlast Pharma Ltd. (BBBT), and others developing therapies for cancer. Panbela's success depends on its ability to navigate the complex regulatory landscape and demonstrate clinical efficacy.
Who Are PBLA's Key Customers?
- Patients with cancer, particularly pancreatic cancer.
- Oncologists and other healthcare professionals who treat cancer patients.
- Hospitals and cancer centers that provide cancer treatment services.
- Potential pharmaceutical partners interested in licensing or acquiring Panbela's products.
Forward Outlook
Wall Street analysts project Panbela Therapeutics, Inc. revenue of about $8.4M for fiscal 2026, with EPS near $-3.43.
PBLA Valuation & Market Position
Relative to its peer group, PBLA's quantitative score of 42/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for Panbela Therapeutics, Inc. stands at 396.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.25 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Panbela Therapeutics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Company Profile
Panbela Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waconia, US. The company is led by CEO Jennifer K. Simpson. PBLA has traded publicly since 2017.
PBLA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Panbela's upcoming clinical trials, indicating strong belief in the company's potential.
- Community sentiment has shifted positively as discussions around innovative cancer therapies gain traction, enhancing visibility.
- The company's focus on addressing unmet medical needs resonates with investors looking for impactful health solutions.
- Recent news about partnerships for drug development has sparked optimism about accelerated growth and market entry.
Bear Case
- Concerns about funding and cash flow have surfaced, raising questions about the company's ability to sustain operations in the long term.
- Market perception remains cautious due to the high risk associated with biotech stocks, especially those in early-stage development.
- Negative sentiment from a segment of the community points to skepticism about the effectiveness of Panbela's therapies based on previous trial results.
- Increased competition in the oncology space could dilute Panbela's market share, leading to bearish outlooks among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PBLA Latest News
No recent news available for PBLA.
PBLA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PBLA.
Price Targets
Wall Street price target analysis for PBLA.
PBLA MoonshotScore
What does this score mean?
The MoonshotScore rates PBLA 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jennifer K. Simpson
CEO
Jennifer K. Simpson serves as the CEO of Panbela Therapeutics, leading a team of 7 employees. Her background includes experience in the biopharmaceutical industry, with a focus on drug development and clinical trials. She has a proven track record of managing and advancing early-stage drug candidates through the clinical development process. Her expertise spans across various therapeutic areas, including oncology. Simpson's leadership is crucial for guiding Panbela through its clinical trials and potential commercialization phases.
Track Record: Under Jennifer K. Simpson's leadership, Panbela Therapeutics has focused on advancing SBP-101 through clinical trials. She has overseen the company's strategic direction, including its focus on pancreatic cancer and other cancer indications. Her key decisions have included prioritizing the development of SBP-101 and seeking strategic partnerships to support the company's growth. She has successfully navigated the challenges of operating a small, clinical-stage biopharmaceutical company.
PBLA OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Panbela Therapeutics may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on this tier may have limited or no financial disclosure, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face fewer regulatory requirements and may be subject to greater price volatility and risk. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Greater price volatility.
- Potential for fraud or manipulation.
- Higher risk of delisting or going out of business.
- Verify the company's registration and regulatory filings.
- Review the company's financial statements (if available).
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Focus on clinical-stage drug development.
- Lead product candidate in Phase Ia/Ib clinical trials.
- Dedicated to developing cancer therapeutics.
- Management team with experience in the biopharmaceutical industry.
- Presence of a website and investor relations materials.
What Investors Ask About Panbela Therapeutics, Inc. (PBLA) — Healthcare
What does the AI Score mean for PBLA?
PBLA holds an AI Score of 42/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer treatment. Their lead product candidate, SBP-101, is undergoing clinical …
What does Panbela Therapeutics, Inc. do?
Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing disruptive therapeutics for the treatment of patients with cancer. The company's lead product candidate, SBP-101, is currently in Phase Ia/Ib clinical trials for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.
What are the main risks for PBLA?
The main risks for Panbela Therapeutics include the potential failure of SBP-101 in clinical trials, regulatory delays or rejection of SBP-101, competition from other companies developing cancer therapeutics, limited financial resources and reliance on external funding, and the OTC market listing indicating higher risk and lower liquidity.
What are the key factors to evaluate for PBLA?
Panbela Therapeutics, Inc. (PBLA) holds an AI score of 42/100 (low). Panbela Therapeutics presents a high-risk, high-reward investment opportunity characteristic of early-stage biotech companies. Not financial advice.
How frequently does PBLA data refresh on this page?
PBLA's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PBLA's recent stock price performance?
Panbela Therapeutics, Inc. (PBLA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a high unmet need in pancreatic cancer. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PBLA overvalued or undervalued right now?
Panbela Therapeutics, Inc. (PBLA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PBLA before investing?
Before investing in Panbela Therapeutics, Inc. (PBLA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PBLA to a portfolio?
Key strength of Panbela Therapeutics, Inc. (PBLA): Focus on a high unmet need in pancreatic cancer. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- OTC market data may be limited and less reliable than exchange-listed data.